Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence study of an abuse-deterrent, extended-release oral morphine product Egalet 001 for the treatment of moderate to severe chronic pain in subjects in a fed state

Next Previous
Search
Trial Profile

Bioequivalence study of an abuse-deterrent, extended-release oral morphine product Egalet 001 for the treatment of moderate to severe chronic pain in subjects in a fed state

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Morphine (Primary)
  • Indications Pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Oct 2016 According to an Egalet media release, an FDA Advisory Committee voted 18 to 1 for approval of ARYMO ER and the Committee recommended ARYMO ER should be labeled as an abuse-deterrent product by the intravenous, nasal and oral routes of abuse.
    • 25 Aug 2016 According to an Egalet media release, the data of from trial would be presented PAINWeek 2016.
    • 29 Feb 2016 According to an Egalet media release, the US FDA has accepted the NDA for ARYMO ER (morphine sulfate) extended-release tablets for the treatment of severe pain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top